C
Celltrion
Global biotech company that launched the world's first monoclonal antibody biosimilar
At a glance
- Status
- Listed
- Founded
- 2002
- Headquarters
- Incheon, South Korea
- Listing
- IPO 2005
- Sector
- Biotech & Life Sciences
- Power Law
- Decacorn$10B+ valuation tierThoroughbred$100M+ revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- KCKT&G Corporation
- VAVaxGen
Source: Dealroom Talent Intelligence.
Global footprint
across markets
Patents
171 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Celltrion was the backer or acquirer, 2021–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
4 deals across Celltrion's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Where Celltrion deploys vs peers
Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.
Celltrion's portfolio, mapped.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Celltrion on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Celltrion on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.